Analysis of peptides in biological fluids by mass spectrometry holds promise of providing diagnostic and prognostic information for cancer and other diseases. Before this technology is used clinically, it is important to understand its advantages and limitations. These are summarized, along with proposals, on how to proceed in the future.
No takes yet. Share an insight, caveat, or question.
Eleftherios P. Diamandis (2006) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: